1. Home
  2. GEO vs ACAD Comparison

GEO vs ACAD Comparison

Compare GEO & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GEO
  • ACAD
  • Stock Information
  • Founded
  • GEO 1984
  • ACAD 1993
  • Country
  • GEO United States
  • ACAD United States
  • Employees
  • GEO N/A
  • ACAD N/A
  • Industry
  • GEO Homebuilding
  • ACAD Biotechnology: Pharmaceutical Preparations
  • Sector
  • GEO Consumer Discretionary
  • ACAD Health Care
  • Exchange
  • GEO Nasdaq
  • ACAD Nasdaq
  • Market Cap
  • GEO 3.9B
  • ACAD 3.8B
  • IPO Year
  • GEO 1994
  • ACAD 2004
  • Fundamental
  • Price
  • GEO $24.64
  • ACAD $21.24
  • Analyst Decision
  • GEO Strong Buy
  • ACAD Buy
  • Analyst Count
  • GEO 5
  • ACAD 19
  • Target Price
  • GEO $44.50
  • ACAD $27.89
  • AVG Volume (30 Days)
  • GEO 3.0M
  • ACAD 2.0M
  • Earning Date
  • GEO 08-06-2025
  • ACAD 08-05-2025
  • Dividend Yield
  • GEO N/A
  • ACAD N/A
  • EPS Growth
  • GEO N/A
  • ACAD N/A
  • EPS
  • GEO 0.23
  • ACAD 1.37
  • Revenue
  • GEO $2,422,677,000.00
  • ACAD $996,283,000.00
  • Revenue This Year
  • GEO $8.72
  • ACAD $13.39
  • Revenue Next Year
  • GEO $27.89
  • ACAD $10.59
  • P/E Ratio
  • GEO $108.90
  • ACAD $15.51
  • Revenue Growth
  • GEO 0.50
  • ACAD 22.42
  • 52 Week Low
  • GEO $11.75
  • ACAD $13.40
  • 52 Week High
  • GEO $36.46
  • ACAD $25.23
  • Technical
  • Relative Strength Index (RSI)
  • GEO 45.37
  • ACAD 47.26
  • Support Level
  • GEO $23.05
  • ACAD $21.16
  • Resistance Level
  • GEO $25.03
  • ACAD $23.09
  • Average True Range (ATR)
  • GEO 0.90
  • ACAD 0.81
  • MACD
  • GEO 0.11
  • ACAD -0.31
  • Stochastic Oscillator
  • GEO 50.26
  • ACAD 3.85

About GEO Geo Group Inc (The) REIT

The GEO Group Inc specializes in detention facilities and community reentry centers. It operates in four segments: U.S. Secure Services, which mainly encompasses U.S.-based secure services business; Electronic Monitoring and Supervision Services, which conducts its services in the United States, represents services provided to adults for monitoring services and evidence-based supervision and treatment programs for community-based parolees, probationers, and pretrial defendants; Reentry Services conducts its services in the United States represents services provided to adults for residential and non-residential treatment, educational and community-based programs, pre-release and half-way house programs; and International Services.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.

Share on Social Networks: